196 related articles for article (PubMed ID: 11535846)
1. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.
Guldenschuh I; Hurlimann R; Muller A; Ammann R; Mullhaupt B; Dobbie Z; Zala GF; Flury R; Seelentag W; Roth J; Meyenberger C; Fried M; Hoppeler T; Spigelman AD; Scott RJ
Dis Colon Rectum; 2001 Aug; 44(8):1090-7; discussion 1097-9. PubMed ID: 11535846
[TBL] [Abstract][Full Text] [Related]
2. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.
Matsumoto T; Nakamura S; Esaki M; Yao T; Iida M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):251-7. PubMed ID: 16460482
[TBL] [Abstract][Full Text] [Related]
3. Primary chemoprevention of familial adenomatous polyposis with sulindac.
Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
[TBL] [Abstract][Full Text] [Related]
4. The role of sulindac in familial adenomatous polyposis patients with ileal pouch polyposis.
Ho JW; Yuen ST; Chung LP; So HC; Kwan KY
Aust N Z J Surg; 1999 Oct; 69(10):756-8. PubMed ID: 10527361
[No Abstract] [Full Text] [Related]
5. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP.
Lynch HT; Smyrk T; McGinn T; Lanspa S; Cavalieri J; Lynch J; Slominski-Castor S; Cayouette MC; Priluck I; Luce MC
Cancer; 1995 Dec; 76(12):2427-33. PubMed ID: 8625067
[TBL] [Abstract][Full Text] [Related]
6. Effect of sulindac treatment for attenuated familial adenomatous polyposis with a new germline APC mutation at codon 161: report of a case.
Esaki M; Matsumoto T; Mizuno M; Kobori Y; Yoshimura R; Yao T; Iida M
Dis Colon Rectum; 2002 Oct; 45(10):1397-402; discussion 1402-6. PubMed ID: 12394442
[TBL] [Abstract][Full Text] [Related]
7. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
[TBL] [Abstract][Full Text] [Related]
8. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
Giardiello FM; Hamilton SR; Krush AJ; Piantadosi S; Hylind LM; Celano P; Booker SV; Robinson CR; Offerhaus GJ
N Engl J Med; 1993 May; 328(18):1313-6. PubMed ID: 8385741
[TBL] [Abstract][Full Text] [Related]
9. Balance between endoscopic and genetic information in the choice of ileorectal anastomosis for familial adenomatous polyposis.
Valanzano R; Ficari F; Curia MC; Aceto G; Veschi S; Cama A; Battista P; Tonelli F
J Surg Oncol; 2007 Jan; 95(1):28-33. PubMed ID: 17192888
[TBL] [Abstract][Full Text] [Related]
10. [The effects of sulindac on the pathology of colorectal remnant polyps of familial adenomatous polyposis (FAP) patients].
Li J; Lv YM; Jin Z; Cui RL
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 37(4):371-3. PubMed ID: 16086054
[TBL] [Abstract][Full Text] [Related]
11. APC genotype, polyp number, and surgical options in familial adenomatous polyposis.
Wu JS; Paul P; McGannon EA; Church JM
Ann Surg; 1998 Jan; 227(1):57-62. PubMed ID: 9445111
[TBL] [Abstract][Full Text] [Related]
12. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.
Itano O; Yang K; Fan K; Kurihara N; Shinozaki H; Abe S; Jin B; Gravaghi C; Edelmann W; Augenlicht L; Kopelovich L; Kucherlapati R; Lamprecht S; Lipkin M
Carcinogenesis; 2009 Nov; 30(11):1923-6. PubMed ID: 19755659
[TBL] [Abstract][Full Text] [Related]
13. [Sulindac in familial adenomatous polyposis coli--preliminary findings of a prospective study].
Müller A; Hürlimann R; Meyenberger C; Staub P; Kobler E; Ammann R
Schweiz Med Wochenschr; 1994 Apr; 124(15):651-4. PubMed ID: 8191270
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
[TBL] [Abstract][Full Text] [Related]
15. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis.
Winde G; Schmid KW; Brandt B; Müller O; Osswald H
Dis Colon Rectum; 1997 Oct; 40(10):1156-68; discussion 1168-9. PubMed ID: 9336110
[TBL] [Abstract][Full Text] [Related]
16. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.
Giardiello FM; Offerhaus JA; Tersmette AC; Hylind LM; Krush AJ; Brensinger JD; Booker SV; Hamilton SR
Gut; 1996 Apr; 38(4):578-81. PubMed ID: 8707091
[TBL] [Abstract][Full Text] [Related]
17. Resorting the function of the colorectal cancer gatekeeper adenomatous polyposis coli.
Kariv R; Caspi M; Fliss-Isakov N; Shorer Y; Shor Y; Rosner G; Brazowski E; Beer G; Cohen S; Rosin-Arbesfeld R
Int J Cancer; 2020 Feb; 146(4):1064-1074. PubMed ID: 31283021
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.
Keller JJ; Offerhaus GJ; Drillenburg P; Caspers E; Musler A; Ristimäki A; Giardiello FM
Clin Cancer Res; 2001 Dec; 7(12):4000-7. PubMed ID: 11751493
[TBL] [Abstract][Full Text] [Related]
20. Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
Burke CA; Dekker E; Lynch P; Samadder NJ; Balaguer F; Hüneburg R; Burn J; Castells A; Gallinger S; Lim R; Stoffel EM; Gupta S; Henderson A; Kallenberg FG; Kanth P; Roos VH; Ginsberg GG; Sinicrope FA; Strassburg CP; Van Cutsem E; Church J; Lalloo F; Willingham FF; Wise PE; Grady WM; Ford M; Weiss JM; Gryfe R; Rustgi AK; Syngal S; Cohen A
N Engl J Med; 2020 Sep; 383(11):1028-1039. PubMed ID: 32905675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
